Long-term effects of progestins on bone quality and fractures

References

• Schindler A E, Campagnoli C, Druckmann R, Huber J, Pasqualini J R, Schweppe K W, Thijssen J HH. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1)S7–S16
   PubMed Web of Science ®Google Scholar
• Thijssen J HH. Overview on the effects of progestins on bone. Maturitas 2003; 46(Suppl 1)S77–S87
   Google Scholar
• Prior J C. Progesterone as a bone-trophic hormone. Endocr Rev 1990; 11: 386–398
   PubMed Web of Science ®Google Scholar
• Dören M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1005. Hum Reprod Update 2000; 6: 419–426
   PubMedGoogle Scholar
• Manolagas S C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115–137
   PubMed Web of Science ®Google Scholar
• Prior J C, Tremollieres F, Forsmo S, Seifert-Klaus V. Unsuccessful attempt to demonstrate progesterone's bone formation actions. Am J Obstet Gynecol 2005; 192: 1502–1503
   Google Scholar
• Peacock M, Turner C H, Econs M J, Foroud T. Genetics of osteoporosis. Endocr Rev 2002; 23: 303–326
   PubMed Web of Science ®Google Scholar
• Wainwright S A, Marshall L M, Ensrud K E, Cauley J A, Black D M, Hillier T A, Hochberg M C, Vogt M T, Orwoll E S. Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90: 2787–2793
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Benevolenskaya L I, Bhalla A K, Cannata J B, Boonen S, Falch J A, Felsenberg D, Finn J D, Nuti R, Hoszowski K, et al. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone 2005; 36: 387–398
   PubMedGoogle Scholar
• Kannus P, Uusi-Rasi K, Palvanen M, Parkkari J. Non-pharmacological means to prevent fractures among older adults. Ann Med 2005; 37: 303–310
   PubMed Web of Science ®Google Scholar
• Cummings S R, Bates D, Black D M. Clinical use of bone densitometry: scientific review. J Am Med Assoc 2002; 288: 1889–1897
   PubMed Web of Science ®Google Scholar
• Soroko S B, Barrett-Connor E, Edelstein S L, Kritz-Silverstein D. Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo study. J Bone Mineral Res 1994; 9: 761–769
   PubMed Web of Science ®Google Scholar
• Nguyen T V, Eisman J A. Genetics of fractures: challenges and opportunities. J Bone Mineral Res 2000; 15: 1253–1256
   PubMedGoogle Scholar
• Ralston S H. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002; 87: 2460–2466
   PubMed Web of Science ®Google Scholar
• Zmuda J M, Sheu J T, Moffett S P. Genetic epidemiology of osteoporosis: past, present and future. Curr Osteoporos 2005; Rep 3: 111–115
   PubMedGoogle Scholar
• Michaëlsson K, Melhus H, Ferm H, Ahlbom A, Pedersen N L. Genetic liability to fractures in the elderly. Arch Intern Med 2005; 185: 1825–1830
   Google Scholar
• Avenell A, Gillespie W J, Gillespie L D, O'Connell D L. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev 2005, 3, CD000227
   Google Scholar
• Bischoff-Ferrari H A, Willett W C, Wong J B, Giovannuci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. J Am Med Assoc 2005; 293: 2257–2264
   PubMed Web of Science ®Google Scholar
• Jackson R D, LaCroix A Z, Gass M, Wallace R B, Robbins J, Lewis C E, Bassford T, Beresford S A, Black H R, Blanchette P, Women's Health Initiative Investigators. Calcium and vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–683
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari H A, Orav E J, Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Ann Intern Med 2006; 166: 424–430
   Google Scholar
• Gennari L, Becherini L, Falchetti A, Masi L, Massart F, Brandi M L. Genetics of osteoporosis: role of steroid hormone receptor polymorphisms. J Steroid Biochem Mol Biol 2002; 81: 1–24
   PubMed Web of Science ®Google Scholar
• Thijssen J HH. Gene polymorphisms involved in the regulation of bone quality. Gynecol Endocrinol 2006; 22: 31–39
   PubMedGoogle Scholar
• Martins S L, Curtis K M, Glasier A F. Combined hormonal contraception and bone health: a systematic review. Contraception 2006; 73: 445–469
   PubMed Web of Science ®Google Scholar
• Curtis K M, Martins S L. Progestogen-only contraception and bone health: a systematic review. Contraception 2006; 73: 470–487
   PubMed Web of Science ®Google Scholar
• WHO statement on hormonal contraception and bone health. Contraception 2006; 73: 443–444
   PubMed Web of Science ®Google Scholar
• Hartard M, Kleinmond C, Luppa P, Zelger O, Egger K, Wiseman M, Weissenbacher E R, Felsenberg D, Erben R G. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception 2006; 74: 367–375
   PubMed Web of Science ®Google Scholar
• Gold M A, Bachrach L K. Contraceptive use in teens: a threat to bone health?. J Adolesc Health 2002; 35: 427–429
   Google Scholar
• Clark M K, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006; 86: 1466–1474
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix A Z, Ichikawa L E, Barlow W F, Ott S M. Changes in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 59: 139–144
   Google Scholar
• Albertazzi P, Bottazzi M, Steel S A. Bone mineral density and depot medroxyprogesterone acetate. Contraception 2006; 73: 577–583
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes A M, Lui-Filho J F, Perrotti M, Petta C A. A prospective study of the forearm bone density of users of etonorgestrel and levonorgestrel releasing contraceptive implants. Hum Reprod 2006; 21: 466–470
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Espejo-Arce X, Hidalgo M M, Hidalgo-Regine C, Teatin-Juliato C A. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel releasing intrauterine system. Hum Reprod 2006; 21: 1316–1319
   PubMed Web of Science ®Google Scholar
• Massai R, Mäkäräinen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod 2005; 20: 2764–2768
   PubMed Web of Science ®Google Scholar
• Uusi-Rasi K, Sievanen H, Heinonen A, Beck T J, Vuori I. Determinants of changes in bone mass and femoral neck structure, and physical performance after menopause: a 9-year follow-up of initially perimenopausal women. Osteoporos Int 2005; 16: 616–622
   PubMedGoogle Scholar
• Hundrup Y A, Hoidrup S, Ekholm O, Davidsen M, Obel E B. Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: the Danish Nurse Cohort Study. Eur J Epidemiol 2004; 19: 1089–1095
   PubMedGoogle Scholar
• Rejnmark L, Vestergaard P, Tofteng C L, Jensen L B, Barenholdt O, Pors Nielsen S, Abrahamsen B, Brixen K, Mosekilde L. Response rates to oestrogen treatment in perimenopausal women: 5-year data from the Danish Osteoporosis Prevention Study (DOPS). Maturitas 2004; 48: 307–320
   PubMedGoogle Scholar
• Liu J H, Muse K N. The effect of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 2005; 192: 1316–1323
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani A R. Postmenopausal femur bone loss: effect of a low dose hormone replacement therapy. Maturitas 2003; 45: 175–183
   PubMed Web of Science ®Google Scholar
• Osmanagaoglu M A, Osmanagaoglu S, Osmanagaoglu T, Bozkaya H. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005; 84: 382–393
   Google Scholar
• Ravn P, Warming L, Christgau S, Christiansen C. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. Bone 2004; 35: 1216–1221
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V, Reeves G, Balkwill A, Barnes I. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. J Am Med Assoc 2004; 291: 2212–2220
   PubMed Web of Science ®Google Scholar
• Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Climacteric 2005; 8(Suppl 3)35–41
   PubMedGoogle Scholar
• Nappi C, Di Spiezio Sardo A, Tommaselli G A, Giordano E, Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet Gynecol 2005; 105: 53–60
   PubMed Web of Science ®Google Scholar
• Grubb G, Spielmann D, Pickar J, Constantine G. Clinical experience with trimegestone as a new progestin in therapy. Steroids 2003; 68: 921–926
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Spielmann D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004; 11: 337–342
   PubMed Web of Science ®Google Scholar
• Collette J, Viethel P, Dethor M, Chevallier T, Micheletti M C, Foidart J M, Reginster J Y. Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal estradiol or equine conjugated estrogen plus nomegestrol acetate. Gynecol Obstet Fertil 2003; 31: 434–441
   PubMedGoogle Scholar
• Nguyen-Pascal M L, Thomas J L, Bergougnoux L, Garnero P, Drapier-Faure E, Delmas P. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period. Climacteric 2005; 8: 136–145
   PubMed Web of Science ®Google Scholar
• Taechakraichana N, Limpaphayom K, Ninlagam T, Panyakhamlerd K, Chaikittisilpa S, Dusitsin N. A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstet Gynecol 2000; 95: 87–94
   PubMedGoogle Scholar
• Liao E Y, Luo X H, Deng X G, Wu X P, Wang P F, Mao J P, Huang G, Wei Q Y. The effect of low dose nylestriol–levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocr Res 2003; 29: 217–226
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher J C, Kleerekoper M, Pickar J H. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005; 16: 372–379
   PubMed Web of Science ®Google Scholar
• Bhattoa H P, Bettembuk P, Balogh A, Szegedi G, Kiss E. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trail. Osteoporos Int 2004; 15: 396–404
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Lees B, Thompson J, Stevenson J C. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Menopause 2005; 12: 331–339
   PubMed Web of Science ®Google Scholar
• Rowan J P, Simon J A, Sperofff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther 2006; 28: 921–932
   PubMed Web of Science ®Google Scholar
• Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgersen L N. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women. Acta Obstet Gynecol Scand 2003; 82: 857–866
   PubMed Web of Science ®Google Scholar
• Popp A W, Bodmer C, Senn C, Fuchs G, Kraenzlin M E, Wyss H, Birkhaeuser M H, Lippuner K. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Maturitas 2006; 53: 191–200
   PubMedGoogle Scholar
• Mizunuma H, Shiraki M, Shintani M, Gorai I, Makita K, Itoga S, Mochizuki Y, Mogi H, Iwaoki Y, Kosha S, et al. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1α-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. J Bone Mineral Res 2006; 24: 11–15
   Google Scholar
• Lydeking-Olsen E, Beck Jensen H E, Setchell K D, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss: a 2 year randomized, placebo-controlled trial. Eur J Nutr 2004; 43: 246–257
   PubMed Web of Science ®Google Scholar
• Tremollieres F, Pouilles J M, Ribot C. Effect of long-term administration of progestogen on postmenopausal bone loss: result of a two-year, controlled randomized study. Clin Endocrinol (Oxf) 1993; 38: 627–631
   PubMed Web of Science ®Google Scholar
• Wermers R A, Hurley D L, Kearns E. Osteoporosis associated with megestrol acetate. Mayo Clin Proc 2004; 79: 1557–1561
   PubMedGoogle Scholar
• Vogel V, Costantino J P, Wickerham D L, Cronin W M, Cecchini R S, Atkins J N, Bevers T B, Fehrenbacher L, Pajon E R, Jr, Wade J L, 3rd, National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Am Med Assoc 2006; 295: 2727–2741
   PubMed Web of Science ®Google Scholar
• Johnson K A. The SERM of my dreams. J Clin Endocrin Metab 2006; 91: 3754–3756
   PubMedGoogle Scholar
• Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21–28
   PubMed Web of Science ®Google Scholar
• Bianco V, Murina F, Valente I. Tibolone in the treatment of menopause: compliance, efficacy and safety in a ten year experience. Minerva Ginecol 2006; 58: 335–344
   PubMedGoogle Scholar
• Riggs B L, Parfitt A M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their activity on bone remodelling. J Bone Miner Res 2005; 20: 177–184
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–578
   PubMed Web of Science ®Google Scholar
• O'Donnell S, Cranney A, Wells G A, Adachi J D, Reginster J Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006, 3, CD005326
   Google Scholar
• Close P, Neuprez A, Reginster J Y. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006; 7: 1603–1615
   PubMed Web of Science ®Google Scholar